Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4454469
Max Phase: Preclinical
Molecular Formula: C86H128N14O28S
Molecular Weight: 1838.11
Molecule Type: Unknown
Associated Items:
ID: ALA4454469
Max Phase: Preclinical
Molecular Formula: C86H128N14O28S
Molecular Weight: 1838.11
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CCCC[C@H](NC(=O)[C@H](Cc1ccc(OS(=O)(=O)O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
Standard InChI: InChI=1S/C86H128N14O28S/c1-2-3-28-63(80(113)92-54-73(103)94-68(50-59-53-91-62-29-22-21-27-61(59)62)83(116)97-64(30-23-24-39-87)81(114)100-70(52-78(110)111)85(118)98-66(79(88)112)48-57-25-17-16-18-26-57)96-82(115)67(49-58-33-35-60(36-34-58)128-129(121,122)123)99-84(117)69(51-77(108)109)95-75(105)56-127-47-45-125-43-41-90-74(104)55-126-46-44-124-42-40-89-71(101)38-37-65(86(119)120)93-72(102)31-19-14-12-10-8-6-4-5-7-9-11-13-15-20-32-76(106)107/h16-18,21-22,25-27,29,33-36,53,63-70,91H,2-15,19-20,23-24,28,30-32,37-52,54-56,87H2,1H3,(H2,88,112)(H,89,101)(H,90,104)(H,92,113)(H,93,102)(H,94,103)(H,95,105)(H,96,115)(H,97,116)(H,98,118)(H,99,117)(H,100,114)(H,106,107)(H,108,109)(H,110,111)(H,119,120)(H,121,122,123)/t63-,64-,65-,66-,67-,68-,69-,70-/m0/s1
Standard InChI Key: CZILUEAKUAUJNL-ASNOGBRRSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1838.11 | Molecular Weight (Monoisotopic): 1836.8743 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Sensfuss U, Kruse T, Skyggebjerg RB, Uldam HK, Vestergaard B, Huus K, Vinther TN, Reinau ME, Schéele S, Clausen TR.. (2019) Structure-Activity Relationships and Characterization of Highly Selective, Long-Acting, Peptide-Based Cholecystokinin 1 Receptor Agonists., 62 (3): [PMID:30624060] [10.1021/acs.jmedchem.8b01558] |
Source(1):